uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's DiseaseGlobeNewsWire • 07/09/24
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MAPRNewsWire • 07/01/24
uniQure Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Investigational Gene Therapy AMT-130 in Huntington's DiseaseGlobeNewsWire • 06/03/24
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 05/07/24
uniQure Announces 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 02/28/24
uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington's DiseaseGlobeNewsWire • 12/19/23
CSL Behring's HEMGENIX® (etranacogene dezaparvovec-drlb) Demonstrates at Three Years Post-Treatment Long-Term Durability, Safety and Greater Bleed Protection Versus Prophylactic Treatment in People Living with Hemophilia BPRNewsWire • 12/12/23
uniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry DiseaseGlobeNewsWire • 11/29/23
Wall Street Analysts Believe uniQure (QURE) Could Rally 405.37%: Here's is How to TradeZacks Investment Research • 11/08/23
uniQure Announces Third Quarter 2023 Financial Results and Highlights Recent Company ProgressGlobeNewsWire • 11/07/23
UniQure (QURE) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 10/25/23
uniQure Announces Major Presence at the European Society of Gene and Cell Therapy (ESGCT) Annual MeetingGlobeNewsWire • 10/24/23
uniQure slashes more than half of its research programs to preserve cashProactive Investors • 10/05/23
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaulMarket Watch • 10/05/23
uniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage ProgramsGlobeNewsWire • 10/05/23